MAPK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Niclosamide, an FDA-approved anthelmintic drug, inhibits the overexpressed ERK/MNK1/eIF4E pathway which makes BP-CML more sensitive to Dasatinib [49].